Allred scoring for ER reporting and it's impact in clearly distinguishing ER negative from ER positive breast cancers

Journal of the Pakistan Medical Association

Volumn 60, Issue 5, 2010, Pages 350-353

  Qureshi, Asim ^a   Pervez, Shahid ^b  

^a SHAUKAT KHANUM MEMORIAL CANCER HOSPITAL AND RESEARCH CENTRE   (Pakistan)

^b AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; ESR1 PROTEIN, HUMAN; ESTROGEN RECEPTOR ALPHA; MONOCLONAL ANTIBODY;

ALLRED METHOD; BREAST CANCER; CHI SQUARE TEST; COMPARATIVE STUDY; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; RETROSPECTIVE STUDY; REVIEW; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; ARTICLE; BREAST TUMOR; CARCINOMA; CLASSIFICATION; FEMALE; IMMUNOLOGY; METABOLISM; METHODOLOGY; PATHOLOGY; REPRODUCIBILITY; STAINING; UNIVERSITY HOSPITAL;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CARCINOMA; ESTROGEN RECEPTOR ALPHA; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; IMMUNOHISTOCHEMISTRY; RECEPTORS, ESTROGEN; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; STAINING AND LABELING;

EID: 77951247164     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Anderson E, Clarke RB, Howell A. Estrogen responsiveness and control of normal human breast proliferation. J Mammary Gland Biol Neoplasia 1998; 3: 23-35.
2. Elledge RM, Green S, Pugh R, Allred DC, Clark GM, Hill J, et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer 2000; 89: 111-7.
3. Clark GM. Prognostic and predictive factors. In: Harris JR, Lippman ME, Morrow M, Hellman S, eds. Diseases of the Breast. Philadelphia: Lippincott-Raven, 1996; pp 461-85.
4. Collins LC, Botero ML, Schnitt SJ. Bimodal frequency distribution of Estrogen Receptor immunohistochemical staining results in breast cancer. Am J Clin Pathol 2005; 123: 16-20.
5. Nisa A, Bhurgri Y, Raza F, Kayani N. Comparison of ER, PR and Her/2 /neu reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer. Asian J Cancer prevention 2008; 9: 553-6.
6. Allred DC, Bustamante MA, Daniel CO. Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance. Arch Surg 1990; 125: 107-13.
7. Taylor CR. Paraffin section immunocytochemistry for estrogen receptor: the time has come. Cancer 1996; 77: 2419-22.
8. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 155-68.
9. Barnes DM, Harris WH, Smith P, Millis RR, Rubens RD. Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer 1996; 74: 1445-51.
10. Pertschuk LP, Feldman JG, Kim YD, Braithwaite L, Schneider F, Braveman AS, et al. Estrogen receptor immunocytochemistry in paraffin embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H222Sp gamma in frozen sections or cytosolbased ligand-binding assays. Cancer 1996; 77: 2514-9.
11. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligandbinding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474-81.
12. Rhodes A, Jasani B, Barnes DM, Bobrow LG, Miller KD. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 2000; 53: 125-30.
13. McCann J. Better assays needed for hormone receptor status, experts say. J Natl Cancer Inst 2001; 93: 579-80.
14. Esteban JM, Ahn C, Mehta P, Battifora H. Biologic significance of quantitative estrogen receptor immunohistochemical assay by image analysis in breast cancer. Am J Clin Pathol 1994; 102: 158-62.
15. Sahin AA, Ordonez N. Quantitative estrogen receptor immunohistochemical analysis of breast cancer: advantages and potential problems. Adv Anat Pathol 1996; 3: 97-100.
16. Lehr HA, Mankoff DA, Corwin D, Santeusanio G, Gown AM. Application of Photoshop-based image analysis to quantification of hormone receptor expression in breast cancer. J Histochem Cytochem 1997; 45: 1559-65.
17. Leong AS-Y, Milios J. Comparison of antibodies to estrogen and progesterone receptors and the influence of microwaveantigen retrieval. Appl Immunohistochem 1993; 1: 282-8.
18. Von Wasielewski R, Mengel M, Nolte M. Influence of fixation, antibody clones, and signal amplification on steroid receptor analysis. Breast J 1998; 4: 33-40.
19. Santeusanio G, Mauriello A, Ventura L, Liberati F, Colantoni A, Lasorella R, et al. Immunohistochemical analysis of estrogen receptors in breast carcinomas using monoclonal antibodies that recognize different domains of the receptor molecule. Appl Immunohistochem Mol Morphol 2000; 8: 275-84.
20. Rhodes A, Jasani B, Balaton AJ, Barnes DM, Anderson E, Bobrow LG, et al. Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in Europe: documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a major contributory element of unreliable assays. Am J Clin Pathol 2001; 115: 44-58.
21. Layfield LJ, Goldstein N, Perkinson KR, Proia AD. Interlaboratory variation in results from immunohistochemical assessment of estrogen receptor status. Breast J 2003; 9: 257-9.
22. Goldstein NS, Ferkowicz M, Odish E. Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol 2003; 120: 86-92.
23. Eifel P, Axelson JA, Costa J, Crowley J, Curran WJ Jr, Deshler A, et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 2001; 93: 979-89.